Stathmin 1 expression did not differ in MPN patients when stratified according to JAK2 mutation status (JAK2WT = 1.08 [range 0.07–6.99] vs. JAK2V617F = 1.61 [range 0.19–8.32], p = 0.20) (Figure 7B) or CALR mutation status (CALRWT=1.48 [0.19–8.32] vs. CALRMUT = 1.08 [range 0.07–6.99], p = 0.45) (Figure 7C). This evidence concerns the gene JAK2 and myeloproliferative disorder.